The Infectious Disease R&D pipeline tracker contains a comprehensive list of approved health products and technologies, as well as candidates in the development pipeline for global health priority issues. It currently reflects the pipeline as of August 2023.
The Infectious Disease R&D pipeline tracker presents data collected as part of the Evidence for Impact project. This project aims to assess the health and economic impact of the past 20 years of investment in R&D for neglected and emerging infectious diseases and it seeks to establish a framework that the community can leverage to track and evaluate the impact of investment in global health R&D on an ongoing basis. The project has been funded by the Bill and Melinda Gates Foundation, Open Philanthropy and Wellcome, supported by an advisory group of more than 40 experts and developed through engagement with more than 100 stakeholders across the entire global health R&D eco-system.
The Infectious Disease R&D pipeline tracker grew out of previous R&D pipeline mapping work undertaken by Policy Cures (published in 2015) and then again by Policy Cures Research in 2019, which was supported by the WHO-TDR and Duke University.
In line with Policy Cures Research’s mission, this tracker provides information on products and candidates for diseases and issues that disproportionately affect people in low- and middle-income countries. It covers all product categories including drugs, vaccines, diagnostics and vector control products, and all stages of research, from early-stage R&D through to product registration. See the ‘Scope’ section below for exact details on the diseases and product areas included in the tracker.
- Download the full database in Excel here.
- An interactive data dashboard is available below.